Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avidin-biotin-dota-90y
- Development stage
- Phase 1
- Lead developer
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intratumoral, Intravesical
01
Overview
Avidin-biotin-dota-90y is a radiopharmaceutical complex used in pretargeted radioimmunotherapy. It consists of the radioactive isotope yttrium-90 (a beta emitter) chelated by DOTA (1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid), which is covalently linked to biotin. This biotinylated complex binds with high affinity to avidin or streptavidin that has been previously localized at the tumor site via a monoclonal antibody conjugate. The strong avidin–biotin interaction allows for highly specific delivery of radiation to tumor cells while minimizing systemic exposure. The drug has been studied in both animal models and clinical trials for various solid tumors including breast cancer and non-muscle invasive bladder cancer[1][3][5][7][10]. Its mechanism relies on delivering targeted beta radiation to destroy residual or microscopic disease after surgical excision or biopsy.
- Other names
- yttrium Y 90 DOTA-biotin
Beyond the preview
Go deeper on avidin-biotin-dota-90y.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avidin-biotin-dota-90y.